222 related articles for article (PubMed ID: 31181107)
1. The cyclophilin inhibitor CRV431 inhibits liver HBV DNA and HBsAg in transgenic mice.
Gallay P; Ure D; Bobardt M; Chatterji U; Ou J; Trepanier D; Foster R
PLoS One; 2019; 14(6):e0217433. PubMed ID: 31181107
[TBL] [Abstract][Full Text] [Related]
2. Alisporivir inhibition of hepatocyte cyclophilins reduces HBV replication and hepatitis B surface antigen production.
Phillips S; Chokshi S; Chatterji U; Riva A; Bobardt M; Williams R; Gallay P; Naoumov NV
Gastroenterology; 2015 Feb; 148(2):403-14.e7. PubMed ID: 25305505
[TBL] [Abstract][Full Text] [Related]
3. Structurally distinct cyclosporin and sanglifehrin analogs CRV431 and NV556 suppress established HCV infection in humanized-liver mice.
Bobardt M; Hansson MJ; Mayo P; Ure D; Foster R; Gallay P
PLoS One; 2020; 15(8):e0237236. PubMed ID: 32764799
[TBL] [Abstract][Full Text] [Related]
4. The Novel Cyclophilin Inhibitor CPI-431-32 Concurrently Blocks HCV and HIV-1 Infections via a Similar Mechanism of Action.
Gallay PA; Bobardt MD; Chatterji U; Trepanier DJ; Ure D; Ordonez C; Foster R
PLoS One; 2015; 10(8):e0134707. PubMed ID: 26263487
[TBL] [Abstract][Full Text] [Related]
5. Antiviral effects of a niobium-substituted heteropolytungstate on hepatitis B virus-transgenic mice.
Li Q; Zhang H; Qi Y; Wang J; Li J; Niu J
Drug Dev Res; 2019 Dec; 80(8):1062-1070. PubMed ID: 31396981
[TBL] [Abstract][Full Text] [Related]
6. Nobiletin, a novel inhibitor, inhibits HBsAg production and hepatitis B virus replication.
Hu Z; Hu J; Ren F; Xu H; Tan M; Wang Q; Ren J
Biochem Biophys Res Commun; 2020 Mar; 523(3):802-808. PubMed ID: 31954513
[TBL] [Abstract][Full Text] [Related]
7. A Pan-Cyclophilin Inhibitor, CRV431, Decreases Fibrosis and Tumor Development in Chronic Liver Disease Models.
Kuo J; Bobardt M; Chatterji U; Mayo PR; Trepanier DJ; Foster RT; Gallay P; Ure DR
J Pharmacol Exp Ther; 2019 Nov; 371(2):231-241. PubMed ID: 31406003
[TBL] [Abstract][Full Text] [Related]
8. Advances in the treatment of hepatitis B virus/hepatitis C virus coinfection.
Sagnelli E; Pisaturo M; Martini S; Sagnelli C; Filippini P; Coppola N
Expert Opin Pharmacother; 2014 Jul; 15(10):1337-49. PubMed ID: 24773464
[TBL] [Abstract][Full Text] [Related]
9. Hepatitis B Gene Therapy Coming to Age.
Soriano V
AIDS Rev; 2018; 20(2):125-127. PubMed ID: 29938706
[TBL] [Abstract][Full Text] [Related]
10. Development of a Novel Site-Specific Pegylated Interferon Beta for Antiviral Therapy of Chronic Hepatitis B Virus.
Tsuge M; Uchida T; Hiraga N; Kan H; Makokha GN; Abe-Chayama H; Miki D; Imamura M; Ochi H; Hayes CN; Shimozono R; Iwamura T; Narumi H; Suzuki T; Kainoh M; Taniguchi T; Chayama K
Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28373196
[TBL] [Abstract][Full Text] [Related]
11. Bardoxolone methyl as a novel potent antiviral agent against hepatitis B and C viruses in human hepatocyte cell culture systems.
Nio Y; Sasai M; Akahori Y; Okamura H; Hasegawa H; Oshima M; Watashi K; Wakita T; Ryo A; Tanaka Y; Hijikata M
Antiviral Res; 2019 Sep; 169():104537. PubMed ID: 31207277
[TBL] [Abstract][Full Text] [Related]
12. HBV Bypasses the Innate Immune Response and Does Not Protect HCV From Antiviral Activity of Interferon.
Mutz P; Metz P; Lempp FA; Bender S; Qu B; Schöneweis K; Seitz S; Tu T; Restuccia A; Frankish J; Dächert C; Schusser B; Koschny R; Polychronidis G; Schemmer P; Hoffmann K; Baumert TF; Binder M; Urban S; Bartenschlager R
Gastroenterology; 2018 May; 154(6):1791-1804.e22. PubMed ID: 29410097
[TBL] [Abstract][Full Text] [Related]
13. Epigallocatechin gallate inhibits hepatitis B virus infection in human liver chimeric mice.
Lai YH; Sun CP; Huang HC; Chen JC; Liu HK; Huang C
BMC Complement Altern Med; 2018 Sep; 18(1):248. PubMed ID: 30189898
[TBL] [Abstract][Full Text] [Related]
14. RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg.
Wooddell CI; Yuen MF; Chan HL; Gish RG; Locarnini SA; Chavez D; Ferrari C; Given BD; Hamilton J; Kanner SB; Lai CL; Lau JYN; Schluep T; Xu Z; Lanford RE; Lewis DL
Sci Transl Med; 2017 Sep; 9(409):. PubMed ID: 28954926
[TBL] [Abstract][Full Text] [Related]
15. Anti-hepatitis B virus activity of wogonin in vitro and in vivo.
Guo Q; Zhao L; You Q; Yang Y; Gu H; Song G; Lu N; Xin J
Antiviral Res; 2007 Apr; 74(1):16-24. PubMed ID: 17280723
[TBL] [Abstract][Full Text] [Related]
16. Inhibiting the Secretion of Hepatitis B Surface Antigen (HBsAg) to Treat Hepatitis B Infection- a Review.
Baugh SDP
Infect Disord Drug Targets; 2017; 17(1):24-35. PubMed ID: 28056752
[TBL] [Abstract][Full Text] [Related]
17. Anti-HBV drugs suppress the growth of HBV-related hepatoma cells via down-regulation of hepatitis B virus X protein.
Zhang S; Gao S; Zhao M; Liu Y; Bu Y; Jiang Q; Zhao Q; Ye L; Zhang X
Cancer Lett; 2017 Apr; 392():94-104. PubMed ID: 28192212
[TBL] [Abstract][Full Text] [Related]
18. Reduction of covalently closed circular DNA with long-term nucleos(t)ide analogue treatment in chronic hepatitis B.
Lai CL; Wong D; Ip P; Kopaniszen M; Seto WK; Fung J; Huang FY; Lee B; Cullaro G; Chong CK; Wu R; Cheng C; Yuen J; Ngai V; Yuen MF
J Hepatol; 2017 Feb; 66(2):275-281. PubMed ID: 27639844
[TBL] [Abstract][Full Text] [Related]
19. Poly(I:C) treatment leads to interferon-dependent clearance of hepatitis B virus in a hydrodynamic injection mouse model.
Wu J; Huang S; Zhao X; Chen M; Lin Y; Xia Y; Sun C; Yang X; Wang J; Guo Y; Song J; Zhang E; Wang B; Zheng X; Schlaak JF; Lu M; Yang D
J Virol; 2014 Sep; 88(18):10421-31. PubMed ID: 24920792
[TBL] [Abstract][Full Text] [Related]
20. Bortezomib inhibits hepatitis B virus replication in transgenic mice.
Bandi P; Garcia ML; Booth CJ; Chisari FV; Robek MD
Antimicrob Agents Chemother; 2010 Feb; 54(2):749-56. PubMed ID: 19949053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
